EPO 018BAlternative Names: EPO-018B; Pegol Sihematide; Peihuaxi hippocampal peptide
Latest Information Update: 28 Oct 2015
At a glance
- Originator Jiangsu Hansoh Pharmaceutical
- Class Anti-inflammatories; Antianaemics; Peptides; Polyethylene glycols
- Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase II Anaemia
Most Recent Events
- 01 Oct 2015 Phase-II clinical trials in Anaemia (In adults, In the elderly, Treatment-experienced) in China (IV) (NCT02586402)